Clinical trials: Prostatic Diseases
Prostate Cancer
Evaluation of Targeted Biopsy Plus Sextant Biopsy in Diagnosis of Prostate Cancer
The goal of this randomized controlled trial (RCT) is to evaluate the efficacy and safety of different prostate biopsy schemes, including targeted biopsy plus sextant biopsy (3TB+6SB) and combination of targeted biopsy and…
- Trial name
- NCT06684652
- Testing
- 3TB+6SB, 3TB+12SB
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University First Hospital
Prostate Cancer, Prostate Neoplasm
Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis.
Multiparametric magnetic resonance imaging (mpMRI) is now widely used to risk stratify men with a suspicion of prostate cancer and identify suspicious regions for biopsy.
- Trial name
- Histo-MRI (NCT04792138)
- Testing
- VERDICT MRI, Luminal Index Imaging
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- University College, London
Prostate Cancer
Evaluation of the Predictive Role of Choline PET/CT on the Survival of Patients Affected by Prostate Cancer.
the increase in the serum PSA (prostate specific antigen) value following radical treatment commonly involves subsequent treatment which, in the absence of morphological evidence of disease recovery, is conducted empirically…
- Trial name
- NCT06158178
- Testing
- Diagnostic accuracy
- Where
- Italy
- Volunteers
- 520 people
- Sponsor
- IRCCS San Raffaele
Prostate Cancer, Magnetic Resonance Imaging
Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols.
- Conditions
- Prostate Cancer, Magnetic Resonance Imaging, Population at Risk
- Trial name
- NCT05384535
- Testing
- Bi-parametric MRI
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Northwell Health
Oncology, Prostate Cancer
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
A [18]F-PSMA-1007 PET/CT or PET/MRI scan are nuclear medicine tests used to create pictures of the whole body that may show where cells that express Prostate-Specific Membrane Antigen (PSMA) are found.
- Trial name
- NCT05712174
- Testing
- [18]F-PSMA-1007
- Where
- Canada
- Volunteers
- 176 people
- Sponsor
- AHS Cancer Control Alberta
Benign Prostatic Hyperplasia
Comparing Rezum and Urolift
This is a randomized controlled trial using a non-inferiority design with the subjects randomized 1:1 to either water vapour thermal treatment (REZUM) arm or prostatic urethral lift (UroLift) arm.
- Trial name
- NCT06820606
- Testing
- Rezum, UroLift
- Where
- Hong Kong
- Volunteers
- 120 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer
Evaluation of Targeted Prostate Biopsies Under MRI: Tolerance and Contribution in the Therapeutic Decision - Exploratory Study
The goal of this clinical trial is to assess the concordance of treatment decisions made in multidisciplinary consultation meeting based on targeted biopsies alone or targeted biopsies associated with systematic biopsies in…
- Trial name
- BIOPROSTATIRM (NCT05612204)
- Testing
- Biopsy under MRI
- Where
- France
- Volunteers
- 51 people
- Sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
Adrenocortical Carcinoma, Breast Cancer
Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT00003038
- Testing
- doxorubicin hydrochloride, suramin
- Where
- United States
- Sponsor
- Mayo Clinic
Prostate Cancer
Validation of Software-based Fusion of Ultrasound and MRI Images of the Prostate
The investigators hypothesize software-based fusion/navigation will be accurate to within 3 mm of the reference standard of EM fusion.
- Trial name
- NCT02882958
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Opioid Consumption, Postoperative, Multimodal Analgesia
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
This prospective, interventional, open-label, phase 3 randomized study evaluates a multimodal analgesia discharge pathway to reduce automatic opioid prescribing following routine robotic-assisted laparoscopic prostatectomy…
- Conditions
- Opioid Consumption, Postoperative, Multimodal Analgesia, Robotic Assisted Laparoscopic Surgery, Robotic Assisted Laparoscopic Radical Prostatectomy
- Trial name
- ROPES (NCT07427043)
- Testing
- multimodal analgesia pathway with up-front small opioid prescription, multimodal analgesia pathway without up-front small opioid prescription, pre-implementation baseline including opioid
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Brigham and Women's Hospital
Prostate Cancer, Cancer of Prostate
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
This is a pilot study of the tolerability and safety of neoadjuvant dapagliflozin for patients with unfavorable intermediate, high-risk, or very high-risk prostatic adenocarcinoma prior to radical prostatectomy.
- Trial name
- NCT04887935
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Urinary Retention
A Prospective Evaluation of the Catheter Science M3 "Mini Catheter" for Patients With Prostatic
The Catheter Science M3 "Mini Catheter" has been developed for management of urinary retention. This temporary device allows for normal functioning of the external striated sphincter.
- Trial name
- NCT03339076
- Testing
- M3 "MINI CATHETER"
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Dr. Gaines W. Hammond Jr. MD FACS
Metastatic Prostate Cancer
CMAB vs IMAB in Metastatic Prostate Cancer
To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer.
- Trial name
- NCT00255268
- Testing
- Goserelin, Bicalutamide
- Where
- 2 sites in Mexico
- Volunteers
- 15 people
- Sponsor
- AstraZeneca
Prostate Cancer
ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer
The purpose of this research study is to assess the effects of ZD4054 on prostate cancer that has spread to the bones by using new imaging techniques.
- Trial name
- NCT01119118
- Testing
- ZD4054
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Wisconsin, Madison
Arthritis of Knee, Arthritis of Hip
Comparison of the Diagnosis Time of VET and SCL in Patients With Intraoperative Coagulopathy
The present study is a prospective, multi-center observational trial comparing the times taken to diagnose coagulopathies using point-of-care (POC) viscoelastic tests or standard central laboratory tests (SCL tests) in patients…
- Conditions
- Arthritis of Knee, Arthritis of Hip, Spine, Prostate Cancer
- Trial name
- NCT06637943
- Testing
- SCL tests, POC viscoelastic tests
- Where
- 4 sites in South Korea
- Volunteers
- 210 people
- Sponsor
- Konkuk University Medical Center
Prostate Cancer
Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases
The aim of the study is to investigate, the effect of radical prostatectomy with extended lymphadenectomy on cancer-specific survival, time to castration-resistance, time to progression and quality of life in patients with a…
- Trial name
- g-RAMPP (NCT02454543)
- Testing
- Radical prostatectomy, Best systemic therapy
- Where
- Germany
- Volunteers
- 452 people
- Sponsor
- Martini-Klinik am UKE GmbH
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
- Trial name
- NCT05413850
- Testing
- Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only)
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 82 people
- Sponsor
- Blue Earth Therapeutics Ltd
Genitourinary Cancer, Adrenocortical Carcinoma
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare…
- Conditions
- Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder, Non-urothelial Upper Tract
- Trial name
- NCT03333616
- Testing
- Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
Prostatic Neoplasms
Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers
Evaluate the effect of darolutamide on the pharmacokinetics of a probe CYP3A4 substrate and Pgp substrate
- Trial name
- NCT03237416
- Testing
- Dabigatran etexilate, Midazolam, BAY1841788 (darolutamide)
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bayer
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
This pilot phase II trial studies how well giving bevacizumab works in treating patients with relapsed prostate cancer that did not respond to hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01656304
- Testing
- bevacizumab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute